Back to today’s briefing

Story perspectives

AstraZeneca Warns UK Investment at Risk Without Reforms

10/9/2025

25 5

Summary

Story summary

AstraZeneca's UK chairman Shaun Grady warned investments in the UK could pause without drug-pricing reforms.
The company has paused or scrapped projects worth hundreds of millions, including a £200 million Cambridge upgrade.
Grady criticized NHS pricing and cost-effectiveness models as deterring innovation and investment.
The UK government has not yet responded to AstraZeneca's concerns about investment risks.

1 of 1

Story summary

AstraZeneca's UK chairman Shaun Grady warned investments in the UK could pause without drug-pricing reforms.
The company has paused or scrapped projects worth hundreds of millions, including a £200 million Cambridge upgrade.
Grady criticized NHS pricing and cost-effectiveness models as deterring innovation and investment.
The UK government has not yet responded to AstraZeneca's concerns about investment risks.